Skip header and navigation

Narrow By

1 records – page 1 of 1.

Golimumab (SimponiĀ®) for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams35651
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1641
Available Online
View Pamphlet
Your health care provider feels that treatment with golimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what golimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (12 p.) : digital, PDF file
Subjects (MeSH)
Golimumab
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Specialty
Medications
Abstract
Your health care provider feels that treatment with golimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what golimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Notes
Previous title: Golimumab (Simponi) therapy
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1641
Less detail